Chairman of the Board: Fatma Al-FarEditor-in-Chief: Ayman Badra

Every sport. Every story.

Latest News
Articles

Why a Long-Term Mega Deal for Tarik Skubal Carries Less Risk Than It Seems

Why a Long-Term Mega Deal for Tarik Skubal Carries Less Risk Than It Seems
Articles · 09:00:04 - Monday, 16 November 2026

The top prize of the upcoming free-agent class is left-hander Tarik Skubal, a two-time Cy Young winner. Projections suggest he could command an 8-to-10-year contract exceeding $400 million, a figure that typically triggers concerns about risk and value. However, a closer look at his track record, workload, injury history, aging patterns among elite pitchers, and recent comparable contracts indicates such a deal may be far less dangerous than the knee-jerk reaction suggests.

Dominant Track Record and Light Workload

Since returning from surgery in 2023, Skubal has been remarkably consistent across his age-26 through age-29 seasons. In 103 starts he has gone 50-20 with a 2.47 ERA (169 ERA+), a 0.92 WHIP, and 757 strikeouts in 626⅓ innings while walking just 109 batters (1.6 per nine). His postseason resume is equally strong: eight starts, a 2.13 ERA, 0.79 WHIP, and 70 strikeouts against nine unintentional walks in 50⅔ innings. Importantly, his career regular-season workload stands at only 925⅓ innings entering his age-30 season — well below the 1,553⅔ innings Justin Verlander had logged at the same age, and even less than the 495 innings Paul Skenes has already accumulated at age 24.

Age and Injury History in Context

Skubal will turn 30 next season, and his medical file includes Tommy John surgery in college, flexor tendon surgery in 2022, and an arthroscopic procedure using a Nanoscope in 2026. Yet such procedures have become commonplace among pitchers, and Skubal's recovery from the latest surgery was swift: he missed roughly six weeks, then made 19 starts with a 2.73 ERA and 141 strikeouts in 115⅓ innings. The pattern across baseball shows that elbow surgery rarely derails elite arms long-term.

Elite Pitchers Age Gracefully in the Modern Era

Recent history offers numerous examples of aces remaining productive deep into their 30s. Verlander won Cy Young awards at 36 and 39; Max Scherzer finished third in Cy Young voting at 36 and posted 5.3 WAR at 37; Chris Sale captured a Cy Young at 35 and excelled at 37; Zack Wheeler returned from thoracic outlet surgery at 36 to produce 6.1 WAR; Jacob deGrom logged a 2.97 ERA in 30 starts at 37; Sonny Gray went 18-5 with a 2.72 ERA at 36; and Zack Greinke remained effective at 38. An eight-year deal for Skubal would cover his age-30 through age-37 seasons — a window in which recent precedents suggest sustained excellence is plausible.

Recent Mega Contracts for Pitchers Have Largely Paid Off

A decade ago, conventional wisdom held that long, expensive pitcher contracts aged poorly. The data since then tells a different story. Gerrit Cole (9 years, $324 million) has delivered 22.4 WAR and a Cy Young through six years. Justin Verlander's 10-year, $219.5 million deal with Detroit included two Cy Youngs, a World Series, and three pennants. Max Scherzer's 7-year, $191.4 million contract yielded 41.8 WAR, two Cy Youngs, and a World Series title. CC Sabathia (9 years, $202 million) posted 27.1 WAR and five consecutive 200-inning seasons. Even deals with injury interruptions — such as Corbin Burnes' 6-year, $210 million pact — have shown early promise. The notable exception, Stephen Strasburg's 7-year, $245 million deal, still netted a World Series championship.

Value Measured in Wins Above Replacement

Using the common benchmark of roughly $8 million per win above replacement (WAR), Skubal's on-field production has been worth an estimated $48.4 million in 2024, $53.7 million in 2025, and $41.7 million in 2026 — figures that far exceed his actual earnings. Over a 10-year, $400 million contract, maintaining even a fraction of that output would represent a bargain relative to the market price of wins.

Given his combination of peak performance, relatively low mileage, successful recovery from recent surgery, and the strong track record of comparable investments, a long-term commitment to Skubal appears less like a gamble and more like a calculated acquisition of a proven ace.

Share this article:FacebookXWhatsAppTelegram